Background: This work aims to present a nuclear medicine imaging service's data regarding applying positron emission–computing tomography (PET/CT) scans with the radiopharmaceutical 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) to diagnose prostate cancer clinical relapse. Methods: Eighty patients with a mean age of 68.26 years with an average prostatic-specific antigen blood level of 7.49 ng/ml (lower concentration = 0.17 ng/ml) received 68Ga-PSMA-11 intravenously, and full-body images of PT-CT scanning were obtained. Of the total of patients admitted to the imaging service, 87.5% were examined for disease's biochemical recurrence and clinical relapse, and 70.0% had a previous radical prostatectomy (RP). Results: Of the patients without RP, 95.8% had detection of intra-glandular disease. The 68Ga-PSMA-11 PET/CT imaging results revealed small lesions, even in patients with low blood levels of prostatic-specific antigen, mainly in metastatic cancer cases in lymph nodes and bones. Conclusion: The 68Ga-PSMA-11 PET/CT imaging was essential in detecting prostate cancer, with significantly high sensitivity in detecting recurrent cases. Due to its inherent reliability and sensitivity, PET/CT scanning with 68Ga-PSMA-11 received an increasing number of medical requests throughout the present follow-up study, confirming the augmented demand for this clinical imaging procedure in the regional medical community.

Over the last few decades, fetal imaging has led to significant improvements in prenatal counseling and postnatal therapy options, as obstetric MRI examination mainly plays a complementary role to the morphological ultrasound study when there is any diagnostic doubt or even to confirm If there is any abnormal finding in the conventional ultrasound exam. It is worth noting that there is no evidence that MRI causes biological effects in the fetus, the exams should be reserved for patients in the second and third trimester of pregnancy. Here, we performed a literature review to point out the importance of the applicability of gestational Magnetic Resonance for the identification of changes in embryonic development, gestational pathologies, maternal diseases, sequelae of infections, fetal malformations, diagnosis of placental deficiency and creation of three-dimensional prototypes for surgical planning and fetal visualization. From this narrative review it was possible to identify that the applicability of gestational MRI is related to the identification of alterations in embryonic development, gestational pathologies in general, maternal diseases, sequelae of infections, fetal malformations, diagnosis of placental deficiency and creation of prototypes three-dimensional (3D) models for surgical planning and fetal visualization.

Not applicable.

Not applicable.